“Godavari biorefineries ltd, through its clinical-stage biotech division sathgen therapeutics, has been granted a patent by the China National Intelligtiutal Administration (CNIPA), China ‘Patent and Trademark Office, for its novel anti-concer molecule-Hydroxy-1,4-Naphthalenendine, “The company informed the bse through the filing.
The company also highlighted that the patent covers a novel class of compounds which show strong inhibitory effects on cancer and cancer stem cells in vitro studies. The compounds under the patent have shown Efficiency Against Multiple Cancer Cell Types, Including Breast and Prostate Cancer.
Godavari Biorefineries is a Major Producer of Ethanol and Eethanol-Based Chemicals in India. The company manufactures bio-based chemicals, sugar, rectified Spirits, Ethanol, other grades of alcohol and power, according to the official website.
Godavari Biorefineries Share Price Trend
Godavari biorefineries shares hit their upper circuit of 326.80 after Gaining 5% on the INTRADAY Market Session on Tuesday, 22 July 2025, Compared to the Previous Day’s Closing Price at 311.25. The company Announced the Patent Update Close to the afternoon session of the stock market.
Shares of the biorefinery firm has given stock market investors Nearly 30% Returns on their Investment in the last one-month period and are currently trading 7.91% Higher in the Last Five MARKET SESSSS Indian Stock Market.
However, Since Its Listing on the Indian Bourses in November 2024, The Stock Has Lost 6.98% but is trading 3.14% higher on a year-to-date (ytd) Basis in 2025.
Godavari Biorefineries Shares Hit Their 52-Veeek High Levels at 408.25 on 9 December 2024, While The 52-Very Low Level was at 145.20 on 28 March 2025, according to the bse data. The company’s market capitalization (M-Cap) Stood at 1,672.43 Crore as of the Stock Market Session on Tuesday, 22 July 2025.
Read all stories by Anubhav mukherjee
Disclaimer: This story is for educational purposes only. The views and recommendations made Above are that of individual analysts or broking companies, and not of mint. We Advise Investors to Check With Certified Experts Before Making Any Investments Decisions.
Discover more from Gautam Kalal
Subscribe to get the latest posts sent to your email.
Be First to Comment